The estimated Net Worth of Jennifer L Good is at least $2.94 Million dollars as of 9 September 2024. Ms. Good owns over 37,241 units of Trevi Therapeutics stock worth over $132,795 and over the last 7 years she sold TRVI stock worth over $0. In addition, she makes $2,810,720 as President, Chief Executive Officer, Co-Founder, and Director at Trevi Therapeutics.
Sign up
Ms. Good TRVI stock SEC Form 4 insiders trading
Jennifer has made over 8 trades of the Trevi Therapeutics stock since 2019, according to the Form 4 filled with the SEC. Most recently she exercised 37,241 units of TRVI stock worth $496,795 on 9 September 2024.
The largest trade she's ever made was exercising 55,121 units of Trevi Therapeutics stock on 3 September 2024 worth over $78,823. On average, Jennifer trades about 6,533 units every 81 days since 2017. As of 9 September 2024 she still owns at least 40,241 units of Trevi Therapeutics stock.
You can see the complete history of Ms. Good stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Jennifer Good biography
Jennifer L. Good serves as President, Chief Executive Officer, Co-Founder, Director of the Company. Ms. Good is our co-founder and has served as a member of our board of directors and as our President and Chief Executive Officer since our inception in March 2011. Previously, Ms. Good served at Penwest Pharmaceuticals Co., or Penwest, from 1997 to 2010, where she held various positions including President and Chief Executive Officer, Chief Operating Officer and Chief Financial Officer. Ms. Good has served on the board of Rhythm Pharmaceuticals, a publicly-traded biopharmaceutical company, since June 2019. Previously, Ms. Good served on the board of Juniper Pharmaceuticals, Inc., a publicly traded healthcare company, from September 2017 until it was acquired by Catalent, Inc. in August 2018. Ms. Good has also served as a board member of the Friedreich’s Ataxia Research Alliance (FARA), a patient advocacy group advancing treatments for the cure of Friedreich’s Ataxia, since 2011. Ms. Good received a Bachelor of Business Administration degree with a concentration in accounting from Pacific Lutheran University in 1987 and is a Certified Public Accountant licensed by the State of Washington, although her license is currently inactive.
What is the salary of Jennifer Good?
As the President, Chief Executive Officer, Co-Founder, and Director of Trevi Therapeutics, the total compensation of Jennifer Good at Trevi Therapeutics is $2,810,720. There are no executives at Trevi Therapeutics getting paid more.
How old is Jennifer Good?
Jennifer Good is 55, she's been the President, Chief Executive Officer, Co-Founder, and Director of Trevi Therapeutics since 2011. There are 14 older and 4 younger executives at Trevi Therapeutics. The oldest executive at Trevi Therapeutics, Inc. is Anne VanLent, 72, who is the Independent Director.
What's Jennifer Good's mailing address?
Jennifer's mailing address filed with the SEC is 222 BERKELEY STREET, 12TH FLOOR, , BOSTON, MA, 02116.
Insiders trading at Trevi Therapeutics
Over the last 5 years, insiders at Trevi Therapeutics have traded over $2,844,492 worth of Trevi Therapeutics stock and bought 79,366,506 units worth $381,350,992 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Forest Baskett, and Scott D Sandell. On average, Trevi Therapeutics executives and independent directors trade stock every 26 days with the average trade being worth of $3,549,117. The most recent stock trade was executed by Jennifer L Good on 6 September 2024, trading 6,059 units of TRVI stock currently worth $8,664.
What does Trevi Therapeutics do?
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.
What does Trevi Therapeutics's logo look like?
Complete history of Ms. Good stock trades at Rhythm Pharmaceuticals and Trevi Therapeutics
Trevi Therapeutics executives and stock owners
Trevi Therapeutics executives and other stock owners filed with the SEC include:
-
Jennifer Good,
President, Chief Executive Officer, Co-Founder, Director -
Thomas Sciascia,
Co-Founder, Chief Medical Officer -
Jennifer L. Good,
Co-Founder, CEO, Pres & Director -
Dr. Thomas R. Sciascia,
Co-Founder & Chief Medical Officer -
Anne VanLent,
Independent Director -
Edward Mathers,
Director -
Michael Heffernan,
Independent Director -
Dominick Colangelo,
Director -
James Cassella,
Independent Director -
Helena Brett-Smith,
Chief Development Officer -
Christopher Seiter,
Chief Financial Officer -
David Meeker,
Independent Chairman of the Board -
Danine Summers,
VP of Medical Affairs -
Dr. William P. Forbes Pharm. D., Pharm.D.,
Chief Devel. Officer -
Christopher Galletta,
Controller & Chief Accounting Officer -
Lisa Delfini,
Chief Financial Officer -
Frank P. Muscolo,
Exec. Officer -
Dr. William P. Forbes Pharm.D., Pharm. D.,
Chief Devel. Officer -
Dr. Amale Hawi,
Sr. VP of CMC -
Christopher J. Seiter,
Chief Financial Officer -
Christopher Galletta,
See Remarks -
Farrell Simon,
Chief Commercial Officer -
Peter W. Sonsini,
10% owner -
Anthony A. Jr. Florence,
10% owner -
Mohamad Makhzoumi,
10% owner -
Frank P Muscolo,
Controller -
Group Holdings (Sbs) Adviso...,
-
Ali Behbahani,
10% owner -
Scott D Sandell,
10% owner -
Yann Mazabraud,
See Remarks -
Enterprise Associates 16, L...,
-
Carmen Chang,
10% owner -
Debra A Drake,
10% owner -
William J Oshea,
10% owner -
Fund V, L.P.Omega Fund V Gp...,
-
David M Mott,
10% owner -
Venture Partners Iv, L.P.Ap...,
-
Eran Nadav,
Director -
Invest A/S Lundbeckfond,
10% owner -
Family Investment Co Vmfic ...,
-
Joshua Makower,
10% owner -
Mette Kirstine Agger,
Director -
Peter J Barris,
10% owner -
Anna Guyer Mitsak,
Director -
Forest Baskett,
10% owner -
King Mellon Foundation Richard,
10% owner -
Paul Edward Walker,
10% owner -
William P Forbes,
Chief Development Officer -
Gp A, Llcbonderman Davidcou...,
-
David J Clark,
Chief Medical Officer -
Lisa Delfini,
Chief Financial Officer